SPDR S&P Pharmaceuticals ETF

XPH

Market cap $175M

SPDR S&P Pharmaceuticals ETF is rated a "Buy" due to compelling valuation and improving technical momentum. XPH offers diversified exposure to large-, mid-, and small-cap pharma stocks, balancing blue-chip stalwarts and speculative biotech. The ETF's price-to-earnings ratio is under 10, and recent share-price momentum has improved, though risk remains due to industry concentration.

The administration has been weighing duties for months on a range of products and ingredients in a national-security tariff investigation.

Pharma's Trump-Pfizer boost sparks momentum, making ETFs PPH, IHE, PJP & XPH attractive for defensive, undervalued growth plays.

President Trump's new tariffs on drugs, trucks, and furniture reignite trade tensions, boosting U.S. manufacturers but raising global costs, pressuring exporters, and adding inflation risks.

What unnerves investors is a lack of clarity on drug pricing.

Drugmakers have been bracing for levies and sought to get ahead of them with pledges to invest billions more on domestic manufacturing.

President Donald Trump said Thursday that he will put import taxes of 100% on pharmaceutical drugs, 50% on kitchen cabinets and bathroom vanities, 30% on upholstered furniture and 25% on heavy trucks starting on Oct. 1.The posts on his social media site showed that Trump's devotion to tariffs did not end with the trade frameworks and import taxes that were launched in August, a reflection of the president's confidence that taxes will help to reduce the government's budget deficit while increasing domestic manufacturing.While Trump did not provide a legal justification for the tariffs, he appeared to stretch the bounds of his role as commander-in-chief by stating on Truth Social that the taxes on imported kitchen cabinets and sofas were needed “for National Security and other reasons.”Under the Trade Expansion Act of 1962, the administration launched a Section 232 investigation in April about the impacts on national security from pharmaceutical drug and truck imports.

Pharmaceutical stocks mostly gained Friday, as traders appeared to shrug off or even cheer President Donald Trump's rollout of a new tariff plan for drugmakers.

President Donald Trump delivered the pharmaceutical industry another blow this week, threatening 100% tariffs on some companies.

Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.